These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17351873)

  • 1. AMPA receptor potentiators as cognitive enhancers.
    O'Neill MJ; Dix S
    IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AMPA receptor modulators as cognitive enhancers.
    Lynch G
    Curr Opin Pharmacol; 2004 Feb; 4(1):4-11. PubMed ID: 15018832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DRUG FOCUS: S 18986: A positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer.
    Bernard K; Danober L; Thomas JY; Lebrun C; Muñoz C; Cordi A; Desos P; Lestage P; Morain P
    CNS Neurosci Ther; 2010 Oct; 16(5):e193-212. PubMed ID: 21050420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.
    Ryder JW; Falcone JF; Manro JR; Svensson KA; Merchant KM
    J Pharmacol Exp Ther; 2006 Oct; 319(1):293-8. PubMed ID: 16803862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for AMPA receptors in mood disorders.
    Alt A; Nisenbaum ES; Bleakman D; Witkin JM
    Biochem Pharmacol; 2006 Apr; 71(9):1273-88. PubMed ID: 16442080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPA receptor potentiators for the treatment of CNS disorders.
    O'Neill MJ; Bleakman D; Zimmerman DM; Nisenbaum ES
    Curr Drug Targets CNS Neurol Disord; 2004 Jun; 3(3):181-94. PubMed ID: 15180479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in positive allosteric modulators of the AMPA receptor.
    Morrow JA; Maclean JK; Jamieson C
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):571-9. PubMed ID: 17002217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AMPA silencing is a prerequisite for developmental long-term potentiation in the hippocampal CA1 region.
    Abrahamsson T; Gustafsson B; Hanse E
    J Neurophysiol; 2008 Nov; 100(5):2605-14. PubMed ID: 18799599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanisms for memory formation].
    Manabe T
    Brain Nerve; 2008 Jul; 60(7):707-15. PubMed ID: 18646610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New fluorinated 1,2,4-benzothiadiazine 1,1-dioxides: discovery of an orally active cognitive enhancer acting through potentiation of the 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors.
    Francotte P; Goffin E; Fraikin P; Lestage P; Van Heugen JC; Gillotin F; Danober L; Thomas JY; Chiap P; Caignard DH; Pirotte B; de Tullio P
    J Med Chem; 2010 Feb; 53(4):1700-11. PubMed ID: 20108934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nefiracetam activation of CaM kinase II and protein kinase C mediated by NMDA and metabotropic glutamate receptors in olfactory bulbectomized mice.
    Moriguchi S; Han F; Shioda N; Yamamoto Y; Nakajima T; Nakagawasai O; Tadano T; Yeh JZ; Narahashi T; Fukunaga K
    J Neurochem; 2009 Jul; 110(1):170-81. PubMed ID: 19457128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term potentiation and cognitive drug discovery.
    Cooke SF; Bliss TV
    Curr Opin Investig Drugs; 2005 Jan; 6(1):25-34. PubMed ID: 15675601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allosteric modulators of AMPA type glutamate receptors a novel gubclass of physiologically active substances].
    Raevskiĭ KS; Eremin KO
    Biomed Khim; 2004; 50(6):523-38. PubMed ID: 15707268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of AMPA receptor trafficking in NMDA receptor-dependent synaptic plasticity in the rat lateral amygdala.
    Yu SY; Wu DC; Liu L; Ge Y; Wang YT
    J Neurochem; 2008 Jul; 106(2):889-99. PubMed ID: 18466342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of learning processes by ionotropic glutamate receptor ligands.
    Danysz W; Zajaczkowski W; Parsons CG
    Behav Pharmacol; 1995 Aug; 6(5 And 6):455-474. PubMed ID: 11224354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMPA receptor ligands: synthetic and pharmacological studies of polyamines and polyamine toxins.
    Strømgaard K; Mellor I
    Med Res Rev; 2004 Sep; 24(5):589-620. PubMed ID: 15224382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ameliorating effects of preadolescent aniracetam treatment on prenatal ethanol-induced impairment in AMPA receptor activity.
    Wijayawardhane N; Shonesy BC; Vaithianathan T; Pandiella N; Vaglenova J; Breese CR; Dityatev A; Suppiramaniam V
    Neurobiol Dis; 2008 Jan; 29(1):81-91. PubMed ID: 17916430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease.
    Yamada KA
    Expert Opin Investig Drugs; 2000 Apr; 9(4):765-78. PubMed ID: 11060708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.